Companies Profiled: The report provides profiles of the companies in the global anti-obesity prescription drugs market such as, F Hoffmann La Roche Ltd, Orexigen Therapeutics, Inc, Novo Nordisk A / S, Arena Pharmaceuticals, Inc, GlaxoSmithKline, VIVUS, Inc, Boehringer Ingelheim, Alizyme and Others. Recently approved Saxenda by Novo Nordisk is growing at a fast growth rate due to rising interest among obese people. Novo Nordisk, an innovator of drugs in the obesity market, introduces Saxenda in all the major markets with a higher dose of glucagon-like peptide-1( GLP-1) receptor agonist, liraglutide, This Dual therapy can be used for both obesity and type 2 diabetes is the latest trend in the market. Click the Below Full Report Link https:// www. infiniumglobalresearch. com / healthcare _ medical _ devices / global _ antiobesity _ prescription _ drugs _ market
Report Highlights: The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the global anti-obesity prescription drugs market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter ' s five forces analysis and DRO analysis of anti-obesity prescription drugs market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the anti-obesity prescription drugs market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. This report will help manufacturers, suppliers and distributors of the antiobesity prescription drugs market to understand the present and future trends in this market and formulate their strategies accordingly.
Infinium Global Research